Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia:: is penicillin useful against intermediately resistant strains?

被引:31
作者
Falcó, V
Almirante, B
Jordano, Q
Calonge, L
del Valle, O
Pigrau, C
Planes, AM
Gavaldà, J
Pahissa, A
机构
[1] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Dept Infect Dis, Barcelona, Spain
[2] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Dept Microbiol, Barcelona, Spain
关键词
beta-lactams; penicillin non-susceptible pneumococci; Streptococcus pneumoniae;
D O I
10.1093/jac/dkh338
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To compare outcome between patients with pneumonia due to penicillin-susceptible S. pneumoniae and patients with pneumonia due to penicillin intermediately resistant strains and to study the outcome of patients with pneumococcal pneumonia caused by strains with MICs of 0.12-1 mg/L treated empirically during the first 48 h with beta-lactam antibiotics. Materials and methods: We studied 247 adult patients with invasive pneumococcal pneumonia occurring from 1997 to 2001. The following data were recorded from each patient: socio-demographic characteristics, underlying diseases, clinical presentation, initial severity of pneumonia, initial and subsequent antimicrobial therapy, in-hospital complications, hospital mortality and length of hospital stay. Multivariate analysis was done to identify variables associated with the development of pneumonia caused by a non-susceptible strain. Results: The overall presence of penicillin non-susceptibility was 26.7%; no strain had an MIC >2 mg/L. Overall mortality was 23.5% in patients with pneumonia caused by intermediately resistant pneumococci and 12.7% in those with pneumonia caused by susceptible strains (P=0.075). Mortality during the first 7 days of admission, considered to be pneumonia-related deaths (13.7% versus 9.9%; P=0.448) was similar in both groups. The multivariate analysis showed that serotype 14 (OR, 140.18; 95% CI, 16.95-1159.20), serotype 19 (OR, 7.53; 95% CI, 1.98-28.7), haematological malignancy or splenectomy (OR, 4.46; 95% CI, 1.5-13.23) and HIV infection (OR, 4.54; 95% CI, 1.54-13.44) were the only independent factors associated with pneumonia caused by penicillin intermediately resistant pneumococci. In patients with strains having MICs of 0.1-1 mg/L, overall mortality was similar in the group of penicillin-treated patients (22.2%) to those treated with broad-spectrum beta-lactams (23.5%). Conclusions: There is a non-significant trend to higher mortality in patients with pneumococcal pneumonia caused by intermediately resistant strains; however, they do not have a poorer outcome when they are treated with amoxicillin.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 24 条
[1]   In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379
[2]  
[Anonymous], 2002, M100S12 NCCLS
[3]   Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae [J].
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S29-S34
[4]   Streptococcus pneumoniae in community-acquired pneumonia -: How important is drug resistance? [J].
Bauer, T ;
Ewig, S ;
Marcos, MA ;
Schultze-Werninghaus, G ;
Torres, A .
MEDICAL CLINICS OF NORTH AMERICA, 2001, 85 (06) :1367-+
[5]   The in vivo-in vitro paradox in pneumococcal respiratory tract infections [J].
Bishai, W .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :433-436
[6]   Pneumococcal drug resistance: The new "special enemy of old age" [J].
Butler, JC ;
Cetron, MS .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (04) :730-735
[7]  
Campbell GD, 1998, CLIN INFECT DIS, V26, P1188, DOI 10.1086/520286
[8]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[9]   Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 [J].
Doern, GV ;
Heilmann, KP ;
Huynh, HK ;
Rhomberg, PR ;
Coffman, SL ;
Brueggemann, AB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1721-1729
[10]   Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae [J].
Ewig, S ;
Ruiz, M ;
Torres, A ;
Marco, F ;
Martinez, JA ;
Sanchez, M ;
Mensa, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (06) :1835-1842